EZH2-IN-7
EZH2-IN-7 is a potent inhibitor of EZH2. EZH2 overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-7 has the potential for the research of cancer diseases (extracted from patent WO2021129629A1, compound 259) [1].
Product Specifications
CAS Number
2659225-28-0
UNSPSC
12352005
Target
Histone Methyltransferase
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Solubility
10 mM in DMSO
Smiles
CSC(C=C(NC1=O)C)=C1C([2H])([2H])NC(C2=C(C)N([C@@H](C3CCC(CC3)OC)C)C4=CC=C(C5=CN(C)N=C5)C=C24)=O
Molecular Formula
C31H37D2N5O3S
Molecular Weight
563.75
References & Citations
[1] Li Yao, et al. Zeste enhancer homologue 2 inhibitor and its use. Patent WO2021129629A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
EZH2
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Scyliorhinus canicula Cytochrome c oxidase subunit 3 (MT-CO3)
Recombinant Scyliorhinus canicula Cytochrome c oxidase subunit 3 (MT-CO3)
Recombinant Scyliorhinus canicula Cytochrome c oxidase subunit 3 (MT-CO3)
